A Multicenter, Randomized, Double-blind, Placebo-Controlled Withdrawal Study to Evaluate the Safety, Tolerability, and Efficacy of Milnacipran in Pediatric Patients With Primary Fibromyalgia.

Trial Profile

A Multicenter, Randomized, Double-blind, Placebo-Controlled Withdrawal Study to Evaluate the Safety, Tolerability, and Efficacy of Milnacipran in Pediatric Patients With Primary Fibromyalgia.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 23 Aug 2012

At a glance

  • Drugs Milnacipran (Primary)
  • Indications Fibromyalgia
  • Focus Therapeutic Use
  • Acronyms MyFi
  • Sponsors Forest Laboratories
  • Most Recent Events

    • 23 Aug 2012 Planned end date changed from 1 Sep 2012 to 1 Aug 2012 as reported by ClinicalTrials.gov record.
    • 01 Aug 2012 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov record.
    • 02 May 2012 Planned end date changed from 1 May 2013 to 1 Sep 2012 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top